D. E. Shaw & Co. Inc. Increases Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

D. E. Shaw & Co. Inc. grew its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 64.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 855,352 shares of the life sciences company’s stock after buying an additional 335,557 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Integra LifeSciences were worth $24,925,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in IART. Capital Research Global Investors grew its position in Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after acquiring an additional 1,621,655 shares in the last quarter. Cooke & Bieler LP boosted its holdings in shares of Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock worth $102,406,000 after purchasing an additional 388,710 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in shares of Integra LifeSciences by 10.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after purchasing an additional 252,015 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after buying an additional 12,766 shares in the last quarter. Finally, Madison Avenue Partners LP lifted its position in Integra LifeSciences by 8.0% in the 4th quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock worth $45,386,000 after buying an additional 77,489 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

NASDAQ IART opened at $17.87 on Friday. The company has a 50-day moving average price of $21.33 and a 200-day moving average price of $27.20. Integra LifeSciences Holdings Co. has a 52 week low of $16.96 and a 52 week high of $45.42. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $1.39 billion, a P/E ratio of 35.74, a PEG ratio of 0.60 and a beta of 1.10.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million for the quarter, compared to the consensus estimate of $413.07 million. During the same period in the previous year, the business earned $0.71 earnings per share. Integra LifeSciences’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

IART has been the topic of a number of recent research reports. Citigroup reduced their price target on shares of Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a research report on Thursday, August 22nd. BTIG Research decreased their target price on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a research report on Wednesday, August 28th. JMP Securities lowered their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. Morgan Stanley lifted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Finally, Truist Financial dropped their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.